AssetMark Inc’s Ensysce Biosciences ENSC Stock Holding History

AssetMark Inc’s Portfolio ENSC Stock Details ENSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13	Closed	-$31	–	3405
2025 Q3	$31	Buy	+13	New	+$28	﹤0.01%	3158

Other funds holding ENSC

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FPI

Financial Plan Inc Bellingham, Washington $933M AUM

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return

TIAM2

Tru Independence Asset Management 2 Portland, Oregon $163M AUM 18.06% 1-Year Est. Return

AssetMark Inc's ENSC Position: Q4 2025 in Review

AssetMark Inc sold out of Ensysce Biosciences (ENSC) in Q4 2025, closing a stake of 13 shares — an estimated $31 sold.

AssetMark Inc first reported a position in ENSC in Q3 2025 and held it in 1 quarter. The position peaked at $31 in Q3 2025. 17 funds tracked by Wall St. Rank hold ENSC as of Q4 2025.

AssetMark Inc reported no remaining Ensysce Biosciences position as of Q4 2025 after selling out during the quarter.
AssetMark Inc sold 13 Ensysce Biosciences shares in Q4 2025, an estimated $31.
AssetMark Inc first reported a position in Ensysce Biosciences in Q3 2025 and held it in 1 quarter.
AssetMark Inc's Ensysce Biosciences position peaked at $31 in Q3 2025.
17 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q4 2025.

Based on AssetMark Inc's 13F filing for Q4 2025, filed 23 Jan 2026.